nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—CYP3A4—Thiotepa—sarcoma	0.0484	0.458	CbGbCtD
Fulvestrant—NR1H4—skull—sarcoma	0.0483	0.17	CbGeAlD
Fulvestrant—CYP3A4—Mitoxantrone—sarcoma	0.0208	0.197	CbGbCtD
Fulvestrant—ESR1—periosteum—sarcoma	0.0185	0.065	CbGeAlD
Fulvestrant—EPHX2—mammary gland—sarcoma	0.0153	0.0537	CbGeAlD
Fulvestrant—ESR2—Validated nuclear estrogen receptor beta network—SMARCB1—sarcoma	0.0147	0.119	CbGpPWpGaD
Fulvestrant—CYP3A4—Vincristine—sarcoma	0.0143	0.136	CbGbCtD
Fulvestrant—CYP3A4—Etoposide—sarcoma	0.0131	0.124	CbGbCtD
Fulvestrant—EPHX2—myometrium—sarcoma	0.0108	0.0381	CbGeAlD
Fulvestrant—NR1H4—hematopoietic system—sarcoma	0.0106	0.0374	CbGeAlD
Fulvestrant—NR1H4—connective tissue—sarcoma	0.0102	0.036	CbGeAlD
Fulvestrant—EPHX2—seminal vesicle—sarcoma	0.00978	0.0344	CbGeAlD
Fulvestrant—ESRRA—myometrium—sarcoma	0.00948	0.0333	CbGeAlD
Fulvestrant—CYP3A4—Doxorubicin—sarcoma	0.00894	0.0847	CbGbCtD
Fulvestrant—ESRRA—seminal vesicle—sarcoma	0.00857	0.0301	CbGeAlD
Fulvestrant—ESR2—Ovarian Infertility Genes—GJA4—sarcoma	0.00837	0.0676	CbGpPWpGaD
Fulvestrant—ESR2—mammary gland—sarcoma	0.00802	0.0282	CbGeAlD
Fulvestrant—EPHX2—uterus—sarcoma	0.00702	0.0247	CbGeAlD
Fulvestrant—ESRRA—cardiac atrium—sarcoma	0.00618	0.0217	CbGeAlD
Fulvestrant—EPHX2—tendon—sarcoma	0.00615	0.0216	CbGeAlD
Fulvestrant—ESRRA—uterus—sarcoma	0.00615	0.0216	CbGeAlD
Fulvestrant—NR1H4—liver—sarcoma	0.00551	0.0194	CbGeAlD
Fulvestrant—ESR1—mammary gland—sarcoma	0.00549	0.0193	CbGeAlD
Fulvestrant—ESRRA—tendon—sarcoma	0.00539	0.0189	CbGeAlD
Fulvestrant—ESRRA—Mitochondrial Gene Expression—CREB1—sarcoma	0.00528	0.0426	CbGpPWpGaD
Fulvestrant—ESRRA—bone marrow—sarcoma	0.00522	0.0184	CbGeAlD
Fulvestrant—EPHX2—testis—sarcoma	0.00509	0.0179	CbGeAlD
Fulvestrant—ESR2—hematopoietic system—sarcoma	0.00489	0.0172	CbGeAlD
Fulvestrant—EPHX2—liver—sarcoma	0.00482	0.0169	CbGeAlD
Fulvestrant—ESR2—connective tissue—sarcoma	0.0047	0.0165	CbGeAlD
Fulvestrant—ESRRA—testis—sarcoma	0.00446	0.0157	CbGeAlD
Fulvestrant—ESR2—smooth muscle tissue—sarcoma	0.0043	0.0151	CbGeAlD
Fulvestrant—NR1H4—lymph node—sarcoma	0.00422	0.0149	CbGeAlD
Fulvestrant—ESRRA—liver—sarcoma	0.00422	0.0148	CbGeAlD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—COL18A1—sarcoma	0.00415	0.0335	CbGpPWpGaD
Fulvestrant—ESR1—myometrium—sarcoma	0.0039	0.0137	CbGeAlD
Fulvestrant—ESR1—embryo—sarcoma	0.00375	0.0132	CbGeAlD
Fulvestrant—EPHX2—lymph node—sarcoma	0.00369	0.013	CbGeAlD
Fulvestrant—ESR2—uterus—sarcoma	0.00369	0.013	CbGeAlD
Fulvestrant—ESR2—lymphoid tissue—sarcoma	0.00344	0.0121	CbGeAlD
Fulvestrant—ESR1—hematopoietic system—sarcoma	0.00335	0.0118	CbGeAlD
Fulvestrant—ESRRA—lymph node—sarcoma	0.00323	0.0114	CbGeAlD
Fulvestrant—ESR1—connective tissue—sarcoma	0.00322	0.0113	CbGeAlD
Fulvestrant—ESR1—LKB1 signaling events—EZR—sarcoma	0.00297	0.024	CbGpPWpGaD
Fulvestrant—ESR1—smooth muscle tissue—sarcoma	0.00295	0.0104	CbGeAlD
Fulvestrant—ESR1—FOXA1 transcription factor network—COL18A1—sarcoma	0.00282	0.0228	CbGpPWpGaD
Fulvestrant—ESR2—testis—sarcoma	0.00268	0.00942	CbGeAlD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—MITF—sarcoma	0.00265	0.0214	CbGpPWpGaD
Fulvestrant—ESRRA—Transcriptional activation of mitochondrial biogenesis—CREB1—sarcoma	0.00265	0.0214	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—IGF1R—sarcoma	0.00263	0.0212	CbGpPWpGaD
Fulvestrant—ESR2—liver—sarcoma	0.00253	0.0089	CbGeAlD
Fulvestrant—ESR1—uterus—sarcoma	0.00253	0.00889	CbGeAlD
Fulvestrant—ESR1—lymphoid tissue—sarcoma	0.00236	0.00829	CbGeAlD
Fulvestrant—ESRRA—Mitochondrial biogenesis—CREB1—sarcoma	0.00229	0.0185	CbGpPWpGaD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—COL18A1—sarcoma	0.00209	0.0169	CbGpPWpGaD
Fulvestrant—ESR2—lymph node—sarcoma	0.00194	0.00683	CbGeAlD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—ATF1—sarcoma	0.00192	0.0155	CbGpPWpGaD
Fulvestrant—CYP3A4—hematopoietic system—sarcoma	0.00187	0.00657	CbGeAlD
Fulvestrant—ESR1—testis—sarcoma	0.00183	0.00645	CbGeAlD
Fulvestrant—ESR1—liver—sarcoma	0.00173	0.0061	CbGeAlD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—MMP2—sarcoma	0.00169	0.0136	CbGpPWpGaD
Fulvestrant—ESR1—Estrogen Receptor Pathway—JUN—sarcoma	0.00165	0.0133	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—WT1—sarcoma	0.00156	0.0126	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—MYOD1—sarcoma	0.00146	0.0118	CbGpPWpGaD
Fulvestrant—ESR1—Estrogen signaling pathway—CREB1—sarcoma	0.00145	0.0117	CbGpPWpGaD
Fulvestrant—Infection—Dactinomycin—sarcoma	0.00136	0.00279	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.00135	0.0109	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Thiotepa—sarcoma	0.00135	0.00278	CcSEcCtD
Fulvestrant—Anaemia—Mitoxantrone—sarcoma	0.00135	0.00277	CcSEcCtD
Fulvestrant—Vertigo—Vincristine—sarcoma	0.00134	0.00276	CcSEcCtD
Fulvestrant—Leukopenia—Vincristine—sarcoma	0.00134	0.00275	CcSEcCtD
Fulvestrant—Skin disorder—Thiotepa—sarcoma	0.00134	0.00275	CcSEcCtD
Fulvestrant—ESR1—lymph node—sarcoma	0.00133	0.00468	CbGeAlD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—IGF1R—sarcoma	0.00133	0.0107	CbGpPWpGaD
Fulvestrant—Anorexia—Thiotepa—sarcoma	0.00131	0.0027	CcSEcCtD
Fulvestrant—Leukopenia—Mitoxantrone—sarcoma	0.0013	0.00268	CcSEcCtD
Fulvestrant—Anorexia—Dactinomycin—sarcoma	0.0013	0.00268	CcSEcCtD
Fulvestrant—Myalgia—Vincristine—sarcoma	0.00127	0.00262	CcSEcCtD
Fulvestrant—Cough—Mitoxantrone—sarcoma	0.00127	0.00261	CcSEcCtD
Fulvestrant—Angiopathy—Etoposide—sarcoma	0.00126	0.0026	CcSEcCtD
Fulvestrant—Immune system disorder—Etoposide—sarcoma	0.00126	0.00259	CcSEcCtD
Fulvestrant—Hepatic failure—Epirubicin—sarcoma	0.00126	0.00258	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Thiotepa—sarcoma	0.00125	0.00258	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.00125	0.00256	CcSEcCtD
Fulvestrant—Chest pain—Mitoxantrone—sarcoma	0.00124	0.00255	CcSEcCtD
Fulvestrant—Myalgia—Mitoxantrone—sarcoma	0.00124	0.00255	CcSEcCtD
Fulvestrant—Arthralgia—Mitoxantrone—sarcoma	0.00124	0.00255	CcSEcCtD
Fulvestrant—Paraesthesia—Thiotepa—sarcoma	0.00124	0.00254	CcSEcCtD
Fulvestrant—Anxiety—Mitoxantrone—sarcoma	0.00124	0.00254	CcSEcCtD
Fulvestrant—Infection—Vincristine—sarcoma	0.00121	0.00249	CcSEcCtD
Fulvestrant—Dyspepsia—Thiotepa—sarcoma	0.00121	0.00249	CcSEcCtD
Fulvestrant—Hot flush—Epirubicin—sarcoma	0.00121	0.00248	CcSEcCtD
Fulvestrant—Nervous system disorder—Vincristine—sarcoma	0.0012	0.00246	CcSEcCtD
Fulvestrant—Decreased appetite—Thiotepa—sarcoma	0.0012	0.00246	CcSEcCtD
Fulvestrant—Menopausal symptoms—Epirubicin—sarcoma	0.0012	0.00246	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Thiotepa—sarcoma	0.00119	0.00245	CcSEcCtD
Fulvestrant—Decreased appetite—Dactinomycin—sarcoma	0.00119	0.00244	CcSEcCtD
Fulvestrant—Fatigue—Thiotepa—sarcoma	0.00119	0.00244	CcSEcCtD
Fulvestrant—Infection—Mitoxantrone—sarcoma	0.00118	0.00243	CcSEcCtD
Fulvestrant—Hyperhidrosis—Vincristine—sarcoma	0.00118	0.00243	CcSEcCtD
Fulvestrant—Fatigue—Dactinomycin—sarcoma	0.00118	0.00242	CcSEcCtD
Fulvestrant—Constipation—Thiotepa—sarcoma	0.00118	0.00242	CcSEcCtD
Fulvestrant—Pain—Thiotepa—sarcoma	0.00118	0.00242	CcSEcCtD
Fulvestrant—Back pain—Etoposide—sarcoma	0.00117	0.00241	CcSEcCtD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—SRC—sarcoma	0.00117	0.00946	CbGpPWpGaD
Fulvestrant—Pain—Dactinomycin—sarcoma	0.00117	0.0024	CcSEcCtD
Fulvestrant—Anorexia—Vincristine—sarcoma	0.00116	0.00239	CcSEcCtD
Fulvestrant—Hepatic failure—Doxorubicin—sarcoma	0.00116	0.00239	CcSEcCtD
Fulvestrant—Skin disorder—Mitoxantrone—sarcoma	0.00116	0.00238	CcSEcCtD
Fulvestrant—Hyperhidrosis—Mitoxantrone—sarcoma	0.00115	0.00236	CcSEcCtD
Fulvestrant—Anorexia—Mitoxantrone—sarcoma	0.00113	0.00233	CcSEcCtD
Fulvestrant—Pain in extremity—Epirubicin—sarcoma	0.00113	0.00232	CcSEcCtD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—NRAS—sarcoma	0.00113	0.0091	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Thiotepa—sarcoma	0.00113	0.00232	CcSEcCtD
Fulvestrant—Anaemia—Etoposide—sarcoma	0.00112	0.0023	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Dactinomycin—sarcoma	0.00112	0.0023	CcSEcCtD
Fulvestrant—Hot flush—Doxorubicin—sarcoma	0.00112	0.00229	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Vincristine—sarcoma	0.00111	0.00229	CcSEcCtD
Fulvestrant—Menopausal symptoms—Doxorubicin—sarcoma	0.00111	0.00228	CcSEcCtD
Fulvestrant—Insomnia—Vincristine—sarcoma	0.0011	0.00227	CcSEcCtD
Fulvestrant—ESR1—Leptin signaling pathway—PLCG1—sarcoma	0.0011	0.00886	CbGpPWpGaD
Fulvestrant—Paraesthesia—Vincristine—sarcoma	0.0011	0.00226	CcSEcCtD
Fulvestrant—Urticaria—Thiotepa—sarcoma	0.00109	0.00225	CcSEcCtD
Fulvestrant—Vertigo—Etoposide—sarcoma	0.00109	0.00224	CcSEcCtD
Fulvestrant—Abdominal pain—Thiotepa—sarcoma	0.00109	0.00224	CcSEcCtD
Fulvestrant—Body temperature increased—Thiotepa—sarcoma	0.00109	0.00224	CcSEcCtD
Fulvestrant—Leukopenia—Etoposide—sarcoma	0.00108	0.00223	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.00108	0.00223	CcSEcCtD
Fulvestrant—Abdominal pain—Dactinomycin—sarcoma	0.00108	0.00222	CcSEcCtD
Fulvestrant—Body temperature increased—Dactinomycin—sarcoma	0.00108	0.00222	CcSEcCtD
Fulvestrant—Paraesthesia—Mitoxantrone—sarcoma	0.00107	0.0022	CcSEcCtD
Fulvestrant—Decreased appetite—Vincristine—sarcoma	0.00106	0.00218	CcSEcCtD
Fulvestrant—Dyspnoea—Mitoxantrone—sarcoma	0.00106	0.00218	CcSEcCtD
Fulvestrant—Cough—Etoposide—sarcoma	0.00106	0.00218	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Vincristine—sarcoma	0.00105	0.00217	CcSEcCtD
Fulvestrant—Fatigue—Vincristine—sarcoma	0.00105	0.00217	CcSEcCtD
Fulvestrant—Dyspepsia—Mitoxantrone—sarcoma	0.00105	0.00215	CcSEcCtD
Fulvestrant—ESR1—Estrogen signaling pathway—JUN—sarcoma	0.00105	0.00844	CbGpPWpGaD
Fulvestrant—Pain—Vincristine—sarcoma	0.00104	0.00215	CcSEcCtD
Fulvestrant—Constipation—Vincristine—sarcoma	0.00104	0.00215	CcSEcCtD
Fulvestrant—Pain in extremity—Doxorubicin—sarcoma	0.00104	0.00215	CcSEcCtD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	0.00104	0.00839	CbGpPWpGaD
Fulvestrant—ESRRA—Organelle biogenesis and maintenance—CREB1—sarcoma	0.00104	0.00839	CbGpPWpGaD
Fulvestrant—Decreased appetite—Mitoxantrone—sarcoma	0.00103	0.00213	CcSEcCtD
Fulvestrant—Chest pain—Etoposide—sarcoma	0.00103	0.00212	CcSEcCtD
Fulvestrant—Fatigue—Mitoxantrone—sarcoma	0.00103	0.00211	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00102	0.00211	CcSEcCtD
Fulvestrant—Breast disorder—Epirubicin—sarcoma	0.00102	0.0021	CcSEcCtD
Fulvestrant—Constipation—Mitoxantrone—sarcoma	0.00102	0.00209	CcSEcCtD
Fulvestrant—Pain—Mitoxantrone—sarcoma	0.00102	0.00209	CcSEcCtD
Fulvestrant—Hypersensitivity—Thiotepa—sarcoma	0.00101	0.00209	CcSEcCtD
Fulvestrant—Hypersensitivity—Dactinomycin—sarcoma	0.00101	0.00207	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Vincristine—sarcoma	0.000999	0.00205	CcSEcCtD
Fulvestrant—Asthenia—Thiotepa—sarcoma	0.000988	0.00203	CcSEcCtD
Fulvestrant—Infection—Etoposide—sarcoma	0.000983	0.00202	CcSEcCtD
Fulvestrant—Asthenia—Dactinomycin—sarcoma	0.000981	0.00202	CcSEcCtD
Fulvestrant—Influenza—Epirubicin—sarcoma	0.000975	0.00201	CcSEcCtD
Fulvestrant—Pruritus—Thiotepa—sarcoma	0.000974	0.002	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000972	0.002	CcSEcCtD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—KRAS—sarcoma	0.00097	0.00783	CbGpPWpGaD
Fulvestrant—CYP3A4—liver—sarcoma	0.000967	0.0034	CbGeAlD
Fulvestrant—Abdominal pain—Vincristine—sarcoma	0.000965	0.00199	CcSEcCtD
Fulvestrant—Body temperature increased—Vincristine—sarcoma	0.000965	0.00199	CcSEcCtD
Fulvestrant—Skin disorder—Etoposide—sarcoma	0.000961	0.00198	CcSEcCtD
Fulvestrant—Hyperhidrosis—Etoposide—sarcoma	0.000956	0.00197	CcSEcCtD
Fulvestrant—Urticaria—Mitoxantrone—sarcoma	0.000945	0.00194	CcSEcCtD
Fulvestrant—Breast disorder—Doxorubicin—sarcoma	0.000943	0.00194	CcSEcCtD
Fulvestrant—Anorexia—Etoposide—sarcoma	0.000943	0.00194	CcSEcCtD
Fulvestrant—Diarrhoea—Thiotepa—sarcoma	0.000942	0.00194	CcSEcCtD
Fulvestrant—Body temperature increased—Mitoxantrone—sarcoma	0.00094	0.00193	CcSEcCtD
Fulvestrant—Abdominal pain—Mitoxantrone—sarcoma	0.00094	0.00193	CcSEcCtD
Fulvestrant—Diarrhoea—Dactinomycin—sarcoma	0.000935	0.00192	CcSEcCtD
Fulvestrant—ESR1—ATF-2 transcription factor network—PDGFRA—sarcoma	0.000927	0.00749	CbGpPWpGaD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—CCND1—sarcoma	0.000917	0.0074	CbGpPWpGaD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—JUN—sarcoma	0.000915	0.00738	CbGpPWpGaD
Fulvestrant—Dizziness—Thiotepa—sarcoma	0.000911	0.00187	CcSEcCtD
Fulvestrant—Influenza—Doxorubicin—sarcoma	0.000902	0.00186	CcSEcCtD
Fulvestrant—Hypersensitivity—Vincristine—sarcoma	0.0009	0.00185	CcSEcCtD
Fulvestrant—Paraesthesia—Etoposide—sarcoma	0.000888	0.00183	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—FUS—sarcoma	0.000886	0.00715	CbGpPWpGaD
Fulvestrant—Dyspnoea—Etoposide—sarcoma	0.000882	0.00181	CcSEcCtD
Fulvestrant—ESR1—LKB1 signaling events—CREB1—sarcoma	0.000882	0.00712	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Mitoxantrone—sarcoma	0.000876	0.0018	CcSEcCtD
Fulvestrant—Asthenia—Vincristine—sarcoma	0.000876	0.0018	CcSEcCtD
Fulvestrant—Vomiting—Thiotepa—sarcoma	0.000876	0.0018	CcSEcCtD
Fulvestrant—Infestation NOS—Epirubicin—sarcoma	0.000869	0.00179	CcSEcCtD
Fulvestrant—Infestation—Epirubicin—sarcoma	0.000869	0.00179	CcSEcCtD
Fulvestrant—Vomiting—Dactinomycin—sarcoma	0.000869	0.00179	CcSEcCtD
Fulvestrant—Rash—Thiotepa—sarcoma	0.000868	0.00179	CcSEcCtD
Fulvestrant—Dermatitis—Thiotepa—sarcoma	0.000867	0.00178	CcSEcCtD
Fulvestrant—Headache—Thiotepa—sarcoma	0.000863	0.00177	CcSEcCtD
Fulvestrant—Rash—Dactinomycin—sarcoma	0.000862	0.00177	CcSEcCtD
Fulvestrant—Decreased appetite—Etoposide—sarcoma	0.00086	0.00177	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Etoposide—sarcoma	0.000854	0.00176	CcSEcCtD
Fulvestrant—Asthenia—Mitoxantrone—sarcoma	0.000853	0.00175	CcSEcCtD
Fulvestrant—Fatigue—Etoposide—sarcoma	0.000853	0.00175	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—MMP2—sarcoma	0.000853	0.00688	CbGpPWpGaD
Fulvestrant—Pain—Etoposide—sarcoma	0.000846	0.00174	CcSEcCtD
Fulvestrant—Constipation—Etoposide—sarcoma	0.000846	0.00174	CcSEcCtD
Fulvestrant—Urinary tract infection—Epirubicin—sarcoma	0.000845	0.00174	CcSEcCtD
Fulvestrant—ESR1—FOXM1 transcription factor network—MMP2—sarcoma	0.000836	0.00675	CbGpPWpGaD
Fulvestrant—Diarrhoea—Vincristine—sarcoma	0.000836	0.00172	CcSEcCtD
Fulvestrant—Sweating—Epirubicin—sarcoma	0.000833	0.00171	CcSEcCtD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—HRAS—sarcoma	0.000825	0.00666	CbGpPWpGaD
Fulvestrant—Hepatobiliary disease—Epirubicin—sarcoma	0.000822	0.00169	CcSEcCtD
Fulvestrant—Nausea—Thiotepa—sarcoma	0.000818	0.00168	CcSEcCtD
Fulvestrant—Diarrhoea—Mitoxantrone—sarcoma	0.000814	0.00167	CcSEcCtD
Fulvestrant—Nausea—Dactinomycin—sarcoma	0.000812	0.00167	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Etoposide—sarcoma	0.000809	0.00166	CcSEcCtD
Fulvestrant—Dizziness—Vincristine—sarcoma	0.000808	0.00166	CcSEcCtD
Fulvestrant—Infestation—Doxorubicin—sarcoma	0.000804	0.00165	CcSEcCtD
Fulvestrant—Infestation NOS—Doxorubicin—sarcoma	0.000804	0.00165	CcSEcCtD
Fulvestrant—Urticaria—Etoposide—sarcoma	0.000786	0.00162	CcSEcCtD
Fulvestrant—Haemoglobin—Epirubicin—sarcoma	0.000784	0.00161	CcSEcCtD
Fulvestrant—Body temperature increased—Etoposide—sarcoma	0.000782	0.00161	CcSEcCtD
Fulvestrant—Abdominal pain—Etoposide—sarcoma	0.000782	0.00161	CcSEcCtD
Fulvestrant—Urinary tract infection—Doxorubicin—sarcoma	0.000782	0.00161	CcSEcCtD
Fulvestrant—Haemorrhage—Epirubicin—sarcoma	0.00078	0.00161	CcSEcCtD
Fulvestrant—Hepatitis—Epirubicin—sarcoma	0.00078	0.00161	CcSEcCtD
Fulvestrant—ESR1—Leptin signaling pathway—FOXO1—sarcoma	0.000779	0.00629	CbGpPWpGaD
Fulvestrant—Vomiting—Vincristine—sarcoma	0.000776	0.0016	CcSEcCtD
Fulvestrant—Pharyngitis—Epirubicin—sarcoma	0.000775	0.00159	CcSEcCtD
Fulvestrant—Sweating—Doxorubicin—sarcoma	0.000771	0.00159	CcSEcCtD
Fulvestrant—Rash—Vincristine—sarcoma	0.00077	0.00158	CcSEcCtD
Fulvestrant—Dermatitis—Vincristine—sarcoma	0.000769	0.00158	CcSEcCtD
Fulvestrant—Oedema peripheral—Epirubicin—sarcoma	0.000769	0.00158	CcSEcCtD
Fulvestrant—Connective tissue disorder—Epirubicin—sarcoma	0.000767	0.00158	CcSEcCtD
Fulvestrant—Headache—Vincristine—sarcoma	0.000765	0.00157	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Doxorubicin—sarcoma	0.000761	0.00156	CcSEcCtD
Fulvestrant—Vomiting—Mitoxantrone—sarcoma	0.000756	0.00156	CcSEcCtD
Fulvestrant—Rash—Mitoxantrone—sarcoma	0.00075	0.00154	CcSEcCtD
Fulvestrant—Dermatitis—Mitoxantrone—sarcoma	0.000749	0.00154	CcSEcCtD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	0.000748	0.00603	CbGpPWpGaD
Fulvestrant—Headache—Mitoxantrone—sarcoma	0.000745	0.00153	CcSEcCtD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—MYC—sarcoma	0.000735	0.00594	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—FOXO1—sarcoma	0.000732	0.00591	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Etoposide—sarcoma	0.000729	0.0015	CcSEcCtD
Fulvestrant—Haemoglobin—Doxorubicin—sarcoma	0.000726	0.00149	CcSEcCtD
Fulvestrant—Nausea—Vincristine—sarcoma	0.000725	0.00149	CcSEcCtD
Fulvestrant—Haemorrhage—Doxorubicin—sarcoma	0.000722	0.00149	CcSEcCtD
Fulvestrant—Hepatitis—Doxorubicin—sarcoma	0.000722	0.00149	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000719	0.0058	CbGpPWpGaD
Fulvestrant—Pharyngitis—Doxorubicin—sarcoma	0.000717	0.00147	CcSEcCtD
Fulvestrant—Oedema peripheral—Doxorubicin—sarcoma	0.000711	0.00146	CcSEcCtD
Fulvestrant—Asthenia—Etoposide—sarcoma	0.00071	0.00146	CcSEcCtD
Fulvestrant—Connective tissue disorder—Doxorubicin—sarcoma	0.00071	0.00146	CcSEcCtD
Fulvestrant—Angiopathy—Epirubicin—sarcoma	0.000708	0.00146	CcSEcCtD
Fulvestrant—Nausea—Mitoxantrone—sarcoma	0.000706	0.00145	CcSEcCtD
Fulvestrant—Immune system disorder—Epirubicin—sarcoma	0.000705	0.00145	CcSEcCtD
Fulvestrant—Pruritus—Etoposide—sarcoma	0.0007	0.00144	CcSEcCtD
Fulvestrant—ESR1—ATF-2 transcription factor network—CREB1—sarcoma	0.000684	0.00553	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000683	0.00551	CbGpPWpGaD
Fulvestrant—Malnutrition—Epirubicin—sarcoma	0.000679	0.0014	CcSEcCtD
Fulvestrant—Diarrhoea—Etoposide—sarcoma	0.000677	0.00139	CcSEcCtD
Fulvestrant—Back pain—Epirubicin—sarcoma	0.000657	0.00135	CcSEcCtD
Fulvestrant—Angiopathy—Doxorubicin—sarcoma	0.000655	0.00135	CcSEcCtD
Fulvestrant—Dizziness—Etoposide—sarcoma	0.000654	0.00135	CcSEcCtD
Fulvestrant—Immune system disorder—Doxorubicin—sarcoma	0.000652	0.00134	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—FUS—sarcoma	0.000648	0.00523	CbGpPWpGaD
Fulvestrant—ESR1—FOXM1 transcription factor network—CCND1—sarcoma	0.000647	0.00523	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—MMP2—sarcoma	0.000637	0.00514	CbGpPWpGaD
Fulvestrant—Vomiting—Etoposide—sarcoma	0.000629	0.00129	CcSEcCtD
Fulvestrant—Malnutrition—Doxorubicin—sarcoma	0.000629	0.00129	CcSEcCtD
Fulvestrant—Anaemia—Epirubicin—sarcoma	0.000628	0.00129	CcSEcCtD
Fulvestrant—Rash—Etoposide—sarcoma	0.000624	0.00128	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—CREB1—sarcoma	0.000624	0.00503	CbGpPWpGaD
Fulvestrant—Dermatitis—Etoposide—sarcoma	0.000623	0.00128	CcSEcCtD
Fulvestrant—ESR1—FOXA1 transcription factor network—JUN—sarcoma	0.000622	0.00503	CbGpPWpGaD
Fulvestrant—Headache—Etoposide—sarcoma	0.00062	0.00127	CcSEcCtD
Fulvestrant—Vertigo—Epirubicin—sarcoma	0.00061	0.00126	CcSEcCtD
Fulvestrant—Leukopenia—Epirubicin—sarcoma	0.000608	0.00125	CcSEcCtD
Fulvestrant—Back pain—Doxorubicin—sarcoma	0.000608	0.00125	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—CREB1—sarcoma	0.000597	0.00482	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.000596	0.00481	CbGpPWpGaD
Fulvestrant—Cough—Epirubicin—sarcoma	0.000593	0.00122	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—SRC—sarcoma	0.000591	0.00477	CbGpPWpGaD
Fulvestrant—Nausea—Etoposide—sarcoma	0.000588	0.00121	CcSEcCtD
Fulvestrant—Anaemia—Doxorubicin—sarcoma	0.000581	0.00119	CcSEcCtD
Fulvestrant—Arthralgia—Epirubicin—sarcoma	0.000578	0.00119	CcSEcCtD
Fulvestrant—Chest pain—Epirubicin—sarcoma	0.000578	0.00119	CcSEcCtD
Fulvestrant—Myalgia—Epirubicin—sarcoma	0.000578	0.00119	CcSEcCtD
Fulvestrant—Anxiety—Epirubicin—sarcoma	0.000576	0.00119	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000574	0.00118	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—NRAS—sarcoma	0.000568	0.00459	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—CREB1—sarcoma	0.000565	0.00456	CbGpPWpGaD
Fulvestrant—Vertigo—Doxorubicin—sarcoma	0.000565	0.00116	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—FUS—sarcoma	0.000564	0.00455	CbGpPWpGaD
Fulvestrant—Leukopenia—Doxorubicin—sarcoma	0.000563	0.00116	CcSEcCtD
Fulvestrant—Infection—Epirubicin—sarcoma	0.000551	0.00113	CcSEcCtD
Fulvestrant—Cough—Doxorubicin—sarcoma	0.000549	0.00113	CcSEcCtD
Fulvestrant—Nervous system disorder—Epirubicin—sarcoma	0.000544	0.00112	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.000539	0.00435	CbGpPWpGaD
Fulvestrant—Skin disorder—Epirubicin—sarcoma	0.000539	0.00111	CcSEcCtD
Fulvestrant—Hyperhidrosis—Epirubicin—sarcoma	0.000536	0.0011	CcSEcCtD
Fulvestrant—Arthralgia—Doxorubicin—sarcoma	0.000535	0.0011	CcSEcCtD
Fulvestrant—Chest pain—Doxorubicin—sarcoma	0.000535	0.0011	CcSEcCtD
Fulvestrant—Myalgia—Doxorubicin—sarcoma	0.000535	0.0011	CcSEcCtD
Fulvestrant—Anxiety—Doxorubicin—sarcoma	0.000533	0.0011	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000532	0.00109	CcSEcCtD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—CREB1—sarcoma	0.000531	0.00429	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.00053	0.00428	CbGpPWpGaD
Fulvestrant—Anorexia—Epirubicin—sarcoma	0.000529	0.00109	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.000525	0.00424	CbGpPWpGaD
Fulvestrant—ESR1—FOXM1 transcription factor network—MYC—sarcoma	0.000519	0.00419	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000518	0.00418	CbGpPWpGaD
Fulvestrant—Infection—Doxorubicin—sarcoma	0.00051	0.00105	CcSEcCtD
Fulvestrant—ESR1—LKB1 signaling events—MYC—sarcoma	0.00051	0.00411	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000505	0.00104	CcSEcCtD
Fulvestrant—Nervous system disorder—Doxorubicin—sarcoma	0.000503	0.00103	CcSEcCtD
Fulvestrant—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000502	0.00405	CbGpPWpGaD
Fulvestrant—Insomnia—Epirubicin—sarcoma	0.000502	0.00103	CcSEcCtD
Fulvestrant—Skin disorder—Doxorubicin—sarcoma	0.000498	0.00102	CcSEcCtD
Fulvestrant—Paraesthesia—Epirubicin—sarcoma	0.000498	0.00102	CcSEcCtD
Fulvestrant—Hyperhidrosis—Doxorubicin—sarcoma	0.000496	0.00102	CcSEcCtD
Fulvestrant—Dyspnoea—Epirubicin—sarcoma	0.000494	0.00102	CcSEcCtD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	0.000493	0.00398	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—CCND1—sarcoma	0.000493	0.00398	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—JUN—sarcoma	0.000492	0.00397	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—KRAS—sarcoma	0.000489	0.00395	CbGpPWpGaD
Fulvestrant—Anorexia—Doxorubicin—sarcoma	0.000489	0.00101	CcSEcCtD
Fulvestrant—Dyspepsia—Epirubicin—sarcoma	0.000488	0.001	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000483	0.0039	CbGpPWpGaD
Fulvestrant—Decreased appetite—Epirubicin—sarcoma	0.000482	0.000991	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Epirubicin—sarcoma	0.000479	0.000984	CcSEcCtD
Fulvestrant—Fatigue—Epirubicin—sarcoma	0.000478	0.000983	CcSEcCtD
Fulvestrant—Pain—Epirubicin—sarcoma	0.000474	0.000975	CcSEcCtD
Fulvestrant—Constipation—Epirubicin—sarcoma	0.000474	0.000975	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.000472	0.00381	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000467	0.000961	CcSEcCtD
Fulvestrant—Insomnia—Doxorubicin—sarcoma	0.000464	0.000954	CcSEcCtD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—CCND1—sarcoma	0.000462	0.00373	CbGpPWpGaD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—JUN—sarcoma	0.000461	0.00372	CbGpPWpGaD
Fulvestrant—Paraesthesia—Doxorubicin—sarcoma	0.000461	0.000947	CcSEcCtD
Fulvestrant—Dyspnoea—Doxorubicin—sarcoma	0.000457	0.000941	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Epirubicin—sarcoma	0.000453	0.000932	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—IL2—sarcoma	0.000452	0.00365	CbGpPWpGaD
Fulvestrant—Dyspepsia—Doxorubicin—sarcoma	0.000452	0.000929	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—JUN—sarcoma	0.000448	0.00362	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.000446	0.0036	CbGpPWpGaD
Fulvestrant—Decreased appetite—Doxorubicin—sarcoma	0.000446	0.000917	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—CTNNB1—sarcoma	0.000445	0.00359	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—FOXO1—sarcoma	0.000445	0.00359	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—ENO2—sarcoma	0.000444	0.00358	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000443	0.000911	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—FOXO1—sarcoma	0.000443	0.00357	CbGpPWpGaD
Fulvestrant—Fatigue—Doxorubicin—sarcoma	0.000442	0.00091	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—PDGFRB—sarcoma	0.000442	0.00357	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—IL2—sarcoma	0.000441	0.00356	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—HBA1—sarcoma	0.000441	0.00356	CbGpPWpGaD
Fulvestrant—Urticaria—Epirubicin—sarcoma	0.00044	0.000906	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—CCND1—sarcoma	0.00044	0.00355	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—JUN—sarcoma	0.000439	0.00355	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000439	0.00354	CbGpPWpGaD
Fulvestrant—Pain—Doxorubicin—sarcoma	0.000439	0.000902	CcSEcCtD
Fulvestrant—Constipation—Doxorubicin—sarcoma	0.000439	0.000902	CcSEcCtD
Fulvestrant—Abdominal pain—Epirubicin—sarcoma	0.000438	0.000901	CcSEcCtD
Fulvestrant—Body temperature increased—Epirubicin—sarcoma	0.000438	0.000901	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—PDGFRA—sarcoma	0.000435	0.00351	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—CCND1—sarcoma	0.00043	0.00347	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—JUN—sarcoma	0.000429	0.00347	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—CTNNB1—sarcoma	0.000426	0.00344	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Doxorubicin—sarcoma	0.00042	0.000863	CcSEcCtD
Fulvestrant—ESR1—LKB1 signaling events—TP53—sarcoma	0.000419	0.00338	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—HRAS—sarcoma	0.000416	0.00336	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Epirubicin—sarcoma	0.000409	0.00084	CcSEcCtD
Fulvestrant—Urticaria—Doxorubicin—sarcoma	0.000408	0.000838	CcSEcCtD
Fulvestrant—ESR1—Leptin signaling pathway—CCND1—sarcoma	0.000407	0.00329	CbGpPWpGaD
Fulvestrant—Abdominal pain—Doxorubicin—sarcoma	0.000406	0.000834	CcSEcCtD
Fulvestrant—Body temperature increased—Doxorubicin—sarcoma	0.000406	0.000834	CcSEcCtD
Fulvestrant—Asthenia—Epirubicin—sarcoma	0.000398	0.000818	CcSEcCtD
Fulvestrant—Pruritus—Epirubicin—sarcoma	0.000392	0.000807	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—VEGFA—sarcoma	0.000392	0.00316	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000382	0.00309	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	0.000382	0.00308	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000381	0.00308	CbGpPWpGaD
Fulvestrant—Diarrhoea—Epirubicin—sarcoma	0.000379	0.00078	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—HRAS—sarcoma	0.000379	0.00306	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000379	0.00306	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Doxorubicin—sarcoma	0.000378	0.000777	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—PLCG1—sarcoma	0.000377	0.00304	CbGpPWpGaD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—MYC—sarcoma	0.000371	0.00299	CbGpPWpGaD
Fulvestrant—Asthenia—Doxorubicin—sarcoma	0.000368	0.000757	CcSEcCtD
Fulvestrant—Dizziness—Epirubicin—sarcoma	0.000367	0.000754	CcSEcCtD
Fulvestrant—ESR1—Leptin signaling pathway—SRC—sarcoma	0.000364	0.00294	CbGpPWpGaD
Fulvestrant—Pruritus—Doxorubicin—sarcoma	0.000363	0.000747	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000362	0.00293	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ENO2—sarcoma	0.000355	0.00287	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—MYC—sarcoma	0.000353	0.00285	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—HBA1—sarcoma	0.000353	0.00285	CbGpPWpGaD
Fulvestrant—Vomiting—Epirubicin—sarcoma	0.000353	0.000725	CcSEcCtD
Fulvestrant—Diarrhoea—Doxorubicin—sarcoma	0.000351	0.000722	CcSEcCtD
Fulvestrant—Rash—Epirubicin—sarcoma	0.00035	0.000719	CcSEcCtD
Fulvestrant—Dermatitis—Epirubicin—sarcoma	0.000349	0.000718	CcSEcCtD
Fulvestrant—Headache—Epirubicin—sarcoma	0.000347	0.000714	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—EGFR—sarcoma	0.000345	0.00279	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—MYC—sarcoma	0.000345	0.00279	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000342	0.00276	CbGpPWpGaD
Fulvestrant—Dizziness—Doxorubicin—sarcoma	0.000339	0.000698	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—KIT—sarcoma	0.000337	0.00272	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000333	0.00269	CbGpPWpGaD
Fulvestrant—Nausea—Epirubicin—sarcoma	0.000329	0.000677	CcSEcCtD
Fulvestrant—Vomiting—Doxorubicin—sarcoma	0.000326	0.000671	CcSEcCtD
Fulvestrant—Rash—Doxorubicin—sarcoma	0.000323	0.000665	CcSEcCtD
Fulvestrant—Dermatitis—Doxorubicin—sarcoma	0.000323	0.000665	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CREB1—sarcoma	0.000323	0.00261	CbGpPWpGaD
Fulvestrant—Headache—Doxorubicin—sarcoma	0.000321	0.000661	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—CREB1—sarcoma	0.000321	0.00259	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	0.000307	0.00248	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	0.000307	0.00248	CbGpPWpGaD
Fulvestrant—Nausea—Doxorubicin—sarcoma	0.000305	0.000627	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—PLCG1—sarcoma	0.000301	0.00243	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	0.0003	0.00242	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—FUS—sarcoma	0.000284	0.0023	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—TP53—sarcoma	0.000283	0.00229	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.000283	0.00229	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000267	0.00216	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MDM2—sarcoma	0.000267	0.00216	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—MDM2—sarcoma	0.000266	0.00214	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—ENO2—sarcoma	0.000259	0.00209	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—HBA1—sarcoma	0.000258	0.00208	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—HRAS—sarcoma	0.000256	0.00207	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	0.000252	0.00203	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—MYC—sarcoma	0.000239	0.00193	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CCND1—sarcoma	0.000233	0.00188	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—JUN—sarcoma	0.000232	0.00187	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	0.00023	0.00186	CbGpPWpGaD
Fulvestrant—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	0.000225	0.00182	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000221	0.00179	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PLCG1—sarcoma	0.00022	0.00178	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—VEGFA—sarcoma	0.000203	0.00164	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—NRAS—sarcoma	0.000199	0.00161	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000193	0.00156	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000192	0.00155	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000191	0.00154	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MYC—sarcoma	0.000187	0.00151	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—EGFR—sarcoma	0.000182	0.00147	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—EGFR—sarcoma	0.000182	0.00147	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—MYC—sarcoma	0.000175	0.00141	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000173	0.00139	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—KRAS—sarcoma	0.000172	0.00139	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—KRAS—sarcoma	0.000171	0.00138	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000168	0.00136	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	0.000155	0.00125	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TP53—sarcoma	0.000153	0.00124	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—MYC—sarcoma	0.000152	0.00123	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	0.000151	0.00122	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—HRAS—sarcoma	0.000146	0.00118	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.000143	0.00115	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	0.000127	0.00102	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TLE1—sarcoma	0.000122	0.000984	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—MYC—sarcoma	0.000115	0.00093	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—VEGFC—sarcoma	0.000103	0.00083	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—MYC—sarcoma	8.42e-05	0.00068	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FLT1—sarcoma	8.22e-05	0.000664	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PLCG1—sarcoma	8.08e-05	0.000652	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CXCR4—sarcoma	7.76e-05	0.000627	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—MYC—sarcoma	7.68e-05	0.00062	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—ATF1—sarcoma	7.68e-05	0.00062	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—MYC—sarcoma	7.33e-05	0.000592	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IGF1R—sarcoma	6.02e-05	0.000486	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FOXO1—sarcoma	5.73e-05	0.000463	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PDGFRB—sarcoma	5.72e-05	0.000462	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PDGFRA—sarcoma	5.63e-05	0.000455	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KDR—sarcoma	4.74e-05	0.000383	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KIT—sarcoma	4.37e-05	0.000353	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CREB1—sarcoma	4.16e-05	0.000336	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ENO2—sarcoma	3.71e-05	0.0003	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—MYC—sarcoma	3.7e-05	0.000298	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—HBA1—sarcoma	3.69e-05	0.000298	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MDM2—sarcoma	3.44e-05	0.000278	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PLCG1—sarcoma	3.15e-05	0.000254	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL2—sarcoma	3.07e-05	0.000248	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCND1—sarcoma	3e-05	0.000242	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—JUN—sarcoma	2.99e-05	0.000241	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CTNNB1—sarcoma	2.97e-05	0.00024	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SRC—sarcoma	2.68e-05	0.000217	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—VEGFA—sarcoma	2.61e-05	0.000211	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NRAS—sarcoma	2.58e-05	0.000208	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MYC—sarcoma	2.4e-05	0.000194	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—EGFR—sarcoma	2.35e-05	0.00019	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KRAS—sarcoma	2.22e-05	0.000179	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TP53—sarcoma	1.97e-05	0.000159	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HRAS—sarcoma	1.89e-05	0.000152	CbGpPWpGaD
